INTRODUCTION {#s1}
============

Central nervous system (CNS) tumors are the second leading cause of death from neurological diseases worldwide, and costs on patients, caregivers and society \[[@R1]\]. Survival chances have improved gradually over the last 30 years but remain poor compared to many other cancers, and 30% glioma survived to one year and 15% glioma survived to five years of patients after diagnosis in adults \[[@R2], [@R3]\]. These data reveal the poor prognosis of CNS tumors, and thus to prevent the occurrence of CNS tumors is essential. The etiology of CNS tumors involves both genetic and environmental factors. Compared with many other cancers, there are only a few identified risk factors for glioma, including increasing age, male, rare genetic syndrome, and high levels of ionizing radiation \[[@R4]\]. Meanwhile, previous studies investigating have showed nonsteroidal anti-inflammatory drugs (NSAIDs) have a chemopreventive potential in the CNS tumors *in vitro* and *in vivo* \[[@R5]\].

NSAIDs are a non-steroidal anti-inflammatory drugs, including aspirin, acetaminophen, indomethacin, naproxen, diclofenac, ibuprofen, nimesulide, rofecoxib and celecoxib. The main function of NSAIDs is anti-inflammatory, antirheumatic, relieve pain and anticoagulation \[[@R6], [@R7]\]. At present, NSAIDs is one of the most widely used drugs in the world. About 30 million people use it every day around the world. As people using NSAIDs increases, clinicians, pharmacists, patients, and society and governments pay more attention to the safety of these drugs.

Previous studies have examined the relationship between NSAIDs use and risk of colorectal cancer \[[@R8]\], stomach cancer \[[@R9]\], prostate cancer \[[@R10]\] and breast cancer \[[@R11]\], have found that NSAIDs use is significantly reduce cancer risk. Even though some studies supported NSAIDs use significantly decrease the risk of CNS tumors \[[@R12]--[@R23]\]. However, the result remains controversial. Additionally, no study to quantitative assessed NSAIDs use in relation to CNS tumors. Thus, we performed this dose-response meta-analysis to clarify and quantitative assessed the correlation between NSAIDs use and CNS tumors risk.

RESULTS {#s2}
=======

Literature search results {#s2_1}
-------------------------

Figure [1](#F1){ref-type="fig"} shows literature research and selection. A total of 2215 studies from PubMed and 2547 studies from Embase. After exclusion of duplicates and studies that did not fulfill the inclusion criteria, 12 studies were chosen, and the data were extracted. These studies were published update to July 2017.

![Flow diagram of the study selection process](oncotarget-08-102486-g001){#F1}

Study characteristics {#s2_2}
---------------------

The characteristics of the included studies of NSAIDs use and CNS tumors risk are shown in the Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Results in different subgroups were treated as two separate reports. Finally, thirty-three independent reports from twelve studies investigated the association between NSAIDs use and CNS tumors risk. Among the selected reports, twenty-two reports investigated the association between non-aspirin NSAIDs use and CNS tumors risk, eleven reports investigated the association between aspirin use and CNS tumors risk. A total of 667085 participants with 19394 incident cases from three countries were included in this meta-analysis.

###### Characteristics of participants in included studies of nonsteroidal anti-inflammatory drugs using in relation to risk of central nervous system tumor

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author(year)                Study design               Country          Sex of population   Age at baseline (years)   No of participants   Endpoints (cases)       Quality score
  --------------------------- -------------------------- ---------------- ------------------- ------------------------- -------------------- ----------------------- ---------------
  Bannon et al. (2013)        Case-control               United Kingdom   Mix                 58.0                      47730                Brain tumours (5052)\   7
                                                                                                                                             Gliomas (2313)\         
                                                                                                                                             Meningiomas (861)       

  Gaist et al. (2013)         Case-control               Denmark          Mix                 20--85                    21536                Gliomas (2688)          7

  Sivak-Sears et al. (2004)   Case-control               USA              Mix                 51--71.5                  637                  Glioblastoma (236)      7

  Scheurer et al. (2008)      Case-control               USA              Mix                 50                        925                  Gliomas (325)           6

  Scheurer et al. (2011)      Case-control               USA              Mix                 53.5                      2873                 Gliomas (1339)          7

  Ferris et al. (2012)        Case-control               USA              Mix                 57.4                      917                  Gliomas (517)           6

  Seliger et al. (2015)       Case-control               United Kingdom   Mix                 55.5                      22055                Gliomas (2005)          7

  Seliger et al. (2016)       Case-control               United Kingdom   Mix                 55.3                      27159                Gliomas (2469)          7

  Friis et al. (2003)         Cohort                     Denmark          Mix                 70.0                      29470                Brain tumours (193)     7

  Sørensen et al. (2003)      Cohort                     USA              Mix                 47.2                      172057               Brain tumours (170)     8

  Daugherty et al. (2011)     Cohort                     USA              Mix                 63.4                      302767               Gliomas (674)\          7
                                                                                                                                             Glioblastoma (521)      

  Cook et al. (2005)          Randomizedclinical trial   USA              Female              54.6                      39876                Brain tumours (31)      6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Outcomes and covariates of included studies of nonsteroidal anti-inflammatory drugs using in relation to risk of central nervous system tumor

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)               Endpoints               Data source         Category and relative risk (95% CI)                                                                                                                          Covariates in fully adjusted model
  --------------------------- ----------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bannon et al. (2013)        Brain tumours (5052)\   Population-based    **Non-aspirin NSAIDs**\                                                                                                                                      Adjusted for age,sex, history of osteoarthritis/arthralgia;history of rheumatoid arthritis, history of allergy, history of hormone replacement therapy use.
                              Gliomas (2313)\                             **Gliomas**\                                                                                                                                                 
                              Meningiomas (861)                           0 DDDs, 1.0 (reference); \> 0- \< 28, 1.00 (0.85, 1.16); \> 28- \< 65, 0.99 (0.85, 1.16); \> 65- \< 212, 1.21 (1.04, 1.40); \> 212, 0.96 (0.82, 1.1.13)\     
                                                                          **Meningiomas**\                                                                                                                                             
                                                                          0 DDDs, 1.0 (reference); \> 0- \< 28, 1.02 (0.79, 1.31); \> 28- \< 65,1.40 (1.10, 1.77); \> 65- \< 212, 1.32 (1.04, 1.67); \> 212, 1.35 (1.06, 1.71)\        
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          **Gliomas**\                                                                                                                                                 
                                                                          0 DDDs, 1.0 (reference); \> 0- \< 224, 1.08 (0.85, 1.38); \> 224- \< 728, 1.09 (0.86, 1.40); \> 728- \< 1572, 1.01(0.78,1.31); \> 1572, 0.85 (0.65, 1.12)\   
                                                                          **Meningiomas**\                                                                                                                                             
                                                                          0 DDDs, 1.0 (reference); \> 0- \< 224, 1.39 (0.98, 1.97); \> 224- \< 728, 1.29 (0.88, 1.90); \> 728- \< 1572, 0.88 (0.58,1.32); \> 1572, 0.97 (0.64, 1.47)   

  Gaist et al. (2013)         Gliomas (2688)          Self-administered   **Recent use, years**\                                                                                                                                       Adjusted for education, diabetes, stroke, allergy, asthma, use of statins, antihistamines, and anti-asthma medication
                                                                          **Non-aspirin NSAIDs**\                                                                                                                                      
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 1.06 (0.95, 1.17); \> 2- \< 4, 0.97 (0.60, 1.57); \> 5, 1.11 (0.57, 2.17)\                                           
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 0.96 (0.79, 1.16); \> 2- \< 4, 0.80 (0.60, 1.06); \> 5, 0.80 (0.53, 1.21)\                                           
                                                                          **Past use, years**\                                                                                                                                         
                                                                          **Non-aspirin NSAIDs**\                                                                                                                                      
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 1.05 (0.95, 1.17); \> 2, 0.91 (0.29, 2.83)\                                                                          
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 0.84(0.61, 1.15); \> 2, 0.47 (0.14, 1.15)                                                                            

  Sivak-Sears et al. (2004)   Glioblastoma (236)      Population-based    **Recent use, years**\                                                                                                                                       Adjustment for gender, ethnicity, income, and education
                                                                          **Ibuprofen**\                                                                                                                                               
                                                                          Never use, 1.0 (reference); \> 0- \< 5, 0.32 (0.10, 0.70); \> 5, 1.04 (0.60, 1.80)\                                                                          
                                                                          **Naproxen**\                                                                                                                                                
                                                                          Never use, 1.0 (reference); \> 0- \< 3, 0.75 (0.30, 1.70); \> 3, 0.50 (0.20, 1.20)\                                                                          
                                                                          **Acetaminophen**\                                                                                                                                           
                                                                          Never use, 1.0 (reference); \> 0- \< 10, 0.72 (0.30, 1.50); \> 10, 1.08 (0.60, 2.00)\                                                                        
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 0- \< 10, 0.71 (0.40, 1.20); \> 10, 0.66 (0.40, 1.10)                                                                         

  Scheurer et al. (2011)      Gliomas (1339)          Population-based    **NSAIDs**\                                                                                                                                                  Adjusted for age, race, sex, education, study series, family history of brain tumors, and history of chickenpox and controlled for all other covariates in the table.
                                                                          Never use, 1.0 (reference); \> 0- \< 10, 0.55 (0.35, 0.88); \> 10, 0.65 (0.39, 1.07)                                                                         

  Ferris et al. (2012)        Gliomas (517)           Self-administered   **Recent use, years**\                                                                                                                                       Adjusted for individual statins, NSAIDs, age, race, gender and center
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          \< 6 Months, 1.0 (reference); \> 7- \< 24, 0.57 (0.30, 1.08); \> 25- \< 60, 0.64 (0.38, 1.06); \> 60, 0.80 (0.51, 1.24)\                                     
                                                                          **Ibuprofen**\                                                                                                                                               
                                                                          \< 6 Months, 1.0 (reference); \> 7- \< 24, 1.49 (0.40, 5.54); \> 25- \< 60, 1.06 (0.55, 2.06); \> 60, 1.08 (0.64, 1.84)\                                     
                                                                          **Naproxen**\                                                                                                                                                
                                                                          \< 6 Months, 1.0 (reference); \> 7- \< 24, 3.40 (0.68, 17.34); \> 25- \< 60, 0.85 (0.23, 2.98); \> 60, 0.37 (0.13, 1.11)\                                    
                                                                          **All NSAIDs**\                                                                                                                                              
                                                                          \< 6 Months, 1.0 (reference); \> 7- \< 24, 0.70 (0.35, 1.38); \> 25- \< 60, 0.75 (0.46,1.23); \> 60- \< 120, 0.73 (0.49, 1.08); \> 120, 0.62 (0.38, 1.00)    

  Seliger et al. (2015)       Gliomas (2005)          Population-based    **Number of prescriptions**\                                                                                                                                 Adjusted for age, sex, general practice, number of years of active history in the database, and adjusted for BMI and smoking
                                                                          **NSAIDs**\                                                                                                                                                  
                                                                          Never use, 1.0 (reference); \> 1- \< 9, 0.98 (0.89, 1.08); \> 10, 1.05 (0.84, 1.33)\                                                                         
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 1- \< 14, 0.78 (0.55, 1.11); \> 15, 1.22 (0.76, 1.94)                                                                         

  Seliger et al. (2016)       Gliomas (2469)          Self-administered   **Number of prescriptions**\                                                                                                                                 Adjusted for age, sex, general practice, and number of years of active history in the database, body mass index, smoking, diabetes, congestive heart failure, and all other medications in this table
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 1- \< 9, 0.83(0.60, 1.15); \> 10- \< 29, 0.80 (0.43, 1.50); \> 30, 1.19 (0.66, 2.13)\                                         
                                                                          **COX-2 inhibitors**\                                                                                                                                        
                                                                          Never use, 1.0 (reference); \> 1- \< 9, 1.02 (0.92, 1.13); \> 10- \< 29, 1.01 (0.80, 1.28); \> 30, 1.16 (0.76, 1.55)\                                        
                                                                          **Ibuprofen**\                                                                                                                                               
                                                                          Never use, 1.0 (reference); \> 1- \< 9, 0.95 (0.86, 1.05); \> 10- \< 29, 1.03 (0.77, 1.39); \> 30, 0.94 (0.60, 1.48)\                                        
                                                                          **Naproxen**\                                                                                                                                                
                                                                          Never use, 1.0 (reference); \> 1- \< 9, 0.91 (0.79, 1.05); \> 10- \< 29, 0.52 (0.28, 0.96); \> 30, 1.45 (0.83, 2.52)                                         

  Daugherty et al. (2011)     Gliomas (674)\          Population-based    **Number of prescriptions**\                                                                                                                                 Adjusting for sex, race, and history of heart disease using age as time metric
                              Glioblastoma (521)                          **Glioma**\                                                                                                                                                  
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 1.21(0.91, 1.61); \> 2- \< 6, 1.07 (0.70, 1.62); \> 7, 1.21 (0.88, 1.65)\                                            
                                                                          **Non Aspirin NSAID**\                                                                                                                                       
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 1.06(0.84, 1.33); \> 2- \< 6, 0.87 (0.53, 1.44); \> 7, 0.92 (0.62, 1.36)\                                            
                                                                          **Glioblastoma**\                                                                                                                                            
                                                                          **Aspirin**\                                                                                                                                                 
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 1.30(0.94, 1.80); \> 2- \< 6, 1.06 (0.65, 1.72); \> 7, 1.21 (0.84, 1.75)\                                            
                                                                          **Non Aspirin NSAID**\                                                                                                                                       
                                                                          Never use, 1.0 (reference); \> 0- \< 2, 1.03(0.79, 1.34); \> 2- \< 6, 0.58 (0.30, 1.15); \> 7, 0.96 (0.62, 1.49)                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DDD: defined daily dose.

NSAIDs use and CNS tumors risk {#s2_3}
------------------------------

Thirty-three independent reports from twelve studies investigated the association between NSAIDs use and CNS tumors risk. Compared with no NSAIDs use, NSAIDs use was significantly associated with a lower risk of CNS tumors risk (RR:0.89; 95% CI, 0.81--0.95; *P* = 0.001) (Table [3](#T3){ref-type="table"}). Furthermore, NSAIDs use was associated with significantly a lower risk of glioma (RR:0.92; 95% CI, 0.87--0.98; *P* = 0.012) (Table [3](#T3){ref-type="table"}), glioblastoma (RR:0.86; 95% CI, 0.73--0.98; *P* \< 0.001) (Table [3](#T3){ref-type="table"}) but not meningioma (RR:0.73; 95% CI, 0.48--1.12; *P* = 0.149) (Table [3](#T3){ref-type="table"}). That may be because there isn\'t enough data in meningioma and CNS tumors risk.

###### Stratified analyses of relative risk of central nervous system tumor risk

  Studies groups                                                     No of reports   Relative risk (95% CI)   Heterogeneity   *P* for test   
  ------------------------------------------------------------------ --------------- ------------------------ --------------- -------------- ----------
  Total                                                              33              0.89 (0.81--0.95)        0.000           55.8%          0.001
  Subgroup analyses for nonsteroidal anti-inflammatory drugs using                                                                           
  **Type of drugs use**                                                                                                                      
  Non-aspirin NSAIDs using                                           22              0.86 (0.78--0.92)        0.001           54.9%          0.002
  Aspirin using                                                      11              0.88 (0.79--0.95)        0.014           54.8%          0.006
  **Tumour subtype**                                                                                                                         
  Glioma                                                             18              0.92 (0.87--0.98)        0.000           55.3%          0.012
  Meningioma                                                         2               0.73 (0.48--1.12)        0.135           55.3%          0.149
  Glioblastoma                                                       7               0.86 (0.73--0.98)        0.177           39.1%          \< 0.001
  **Study design**                                                                                                                           
  Case--control                                                      27              0.89 (0.83--0.96)        0.000           60.5%          0.001
  Cohort                                                             6               0.93 (0.83--0.99)        0.256           23.7%          0.043
  **No of participants**                                                                                                                     
  ≥ 10 000                                                           23              0.94 (0.86--0.99)        0.000           57.6%          0.038
  \< 10 000                                                          10              0.72 (0.62--0.83)        0.705           0.0%           \< 0.001
  **No of cases**                                                                                                                            
  ≥1000                                                              21              0.94 (0.87--0.99)        0.000           59.1%          0.041
  \<1000                                                             12              0.80 (0.68--0.90)        0.051           43.8%          \< 0.001
  **Study quality**                                                                                                                          
  Score ≥ 7                                                          30              0.83 (0.73--0.93)        0.000           65.4%          \< 0.001
  Score \< 7                                                         3               0.95 (0.86--1.05)        0.313           0.0%           0.413

Non-aspirin NSAIDs use and CNS tumors risk {#s2_4}
------------------------------------------

Twenty-two independent reports from ten studies investigated the association between non-aspirin NSAIDs use and CNS tumors risk. Non-aspirin NSAIDs use was significantly associated with a lower risk of CNS tumors risk (RR:0.86; 95% CI, 0.78--0.94; *P* = 0.002) (Table [4](#T4){ref-type="table"}). Furthermore, non-aspirin NSAIDs use was associated with significantly a lower risk of glioma (RR:0.94; 95% CI, 0.88--0.99; *P* = 0.042) (Table [4](#T4){ref-type="table"}), glioblastoma (RR:0.78; 95% CI, 0.63--0.95; *P* = 0.014) (Table [4](#T4){ref-type="table"}) but not meningioma (RR:0.97; 95% CI, 0.64--1.47; *P* = 0.880) (Table [4](#T4){ref-type="table"}).

###### Associations between non-aspirin NSAIDs using and central nervous system tumor risk in subgroup meta-analyses

  Studies groups           No of reports   Relative risk (95% CI)   Heterogeneity   *P* for test   
  ------------------------ --------------- ------------------------ --------------- -------------- ----------
  Total                    22              0.86 (0.78--0.92)        0.001           54.9%          0.002
  **Tumour subtype**                                                                               
  Glioma                   16              0.94 (0.88--0.99)        0.003           57.0%          0.042
  Meningioma               1               0.97 (0.64--1.47)                                       0.880
  Glioblastoma             5               0.78 (0.63--0.95)        0.883           0.0%           0.014
  **Study design**                                                                                 
  Case--control            19              0.88 (0.78--0.95)        0.000           60.3%          \< 0.001
  Cohort                   3               0.93 (0.85--0.98)        0.686           0.0%           0.013
  **No of participants**                                                                           
  ≥ 10 000                 17              0.87 (0.78--0.91)        0.000           66.0%          0.003
  \< 10 000                5               0.91 (0.85--0.97)        0.155           46.3%          \< 0.001
  **No of cases**                                                                                  
  ≥ 1000                   11              0.83 (0.73--0.94)        0.162           24.2%          0.005
  \< 1000                  11              0.90 (0.81--0.98)        0.001           65.8%          0.013
  **Study quality**                                                                                
  Score ≥ 7                20              0.88 (0.78--0.98)        0.002           54.6%          0.007
  Score \< 7               2               0.74 (0.67--0.82)        0.448           0.0%           \< 0.001

Aspirin use and CNS tumors risk {#s2_5}
-------------------------------

Eleven independent reports from seven studies investigated the association between aspirin use and CNS tumors risk. Compared with no aspirin use, aspirin use was significantly associated with a lower risk of CNS tumors risk (RR:0.88; 95% CI, 0.79--0.95; *P* = 0.006)(Table [5](#T5){ref-type="table"}). Furthermore, aspirin use was associated with significantly a lower risk of glioma(RR:0.86; 95% CI, 0.76--0.95; *P* \< 0.001) (Table [5](#T5){ref-type="table"}) but not meningioma (RR:0.85; 95% CI, 0.65--1.12; *P* = 0.253) (Table [5](#T5){ref-type="table"}) and glioblastoma (RR:0.91; 95% CI, 0.55--1.50; *P* = 0.701) (Table [5](#T5){ref-type="table"})

###### Associations between aspirin using and central nervous system tumor risk in subgroup meta-analyses

  Studies groups           No of reports   Relative risk (95% CI)   Heterogeneity   *P* for test   
  ------------------------ --------------- ------------------------ --------------- -------------- ----------
  Total                    11              0.88 (0.79--0.95)        0.014           54.8%          0.006
  **Tumour subtype**                                                                               
  Glioma                   8               0.86 (0.76--0.95)        0.013           43.8%          \< 0.001
  Meningioma               1               0.85 (0.65--1.12)                                       0.253
  Glioblastoma             2               0.91 (0.55--1.50)        0.038           76.7%          0.701
  **Study design**                                                                                 
  Case--control            8               0.83 (0.72--0.96)        0.032           54.4%          0.001
  Cohort                   3               0.92 (0.82--0.96)        0.055           65.5%          0.025
  **No of participants**                                                                           
  ≥ 10 000                 10              0.85 (0.75--0.96)        0.021           54.1%          0.003
  \< 10 000                1               1.08 (0.64--1.34)                                       0.651
  **No of cases**                                                                                  
  ≥ 1000                   10              0.85 (0.75--0.96)        0.021           54.1%          0.003
  \< 1000                  1               1.08 (0.64--1.34)                                       0.651
  **Study quality**                                                                                
  Score ≥ 7                10              0.85 (0.75--0.96)        0.021           54.1%          0.003
  Score \< 7               1               1.08 (0.64--1.34)                                       0.651

Dose-response between NSAIDs use and CNS tumors risk {#s2_6}
----------------------------------------------------

Use restricted cubic spline function, the test for a nonlinear dose-response relationship was significant (likelihood ratio test, *P* \< 0.001), suggesting curvature in the relationship between NSAIDs use and CNS tumors risk. Increasing cumulative 100 defined daily dose of NSAIDs use was associated with a 5% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per cumulative 100 defined daily dose of NSAIDs use was 0.95 (95% CI: 0.92--0.98, *P* = 0.003) (Figure [2](#F2){ref-type="fig"}). Furthermore, increasing NSAIDs use (per 3 prescriptions increment) was associated with a 7% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per 3 prescriptions increment of NSAIDs use was 0.93 (95% CI: 0.88--0.97, *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}). Increasing non-aspirin NSAIDs use (per 3 prescriptions increment) was associated with a 7% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per 3 prescriptions increment of non-aspirin NSAIDs use was 0.93 (95% CI: 0.89--0.97, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). Increasing aspirin use (per 3 prescriptions increment) was associated with a 10% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per 3 prescriptions increment of aspirin use was 0.90 (95% CI: 0.85--0.95, *P* \< 0.001) (Figure [5](#F5){ref-type="fig"}). Additionally, increasing per 2 year of duration of NSAIDs use was associated with a 6% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per 2 year of duration of NSAIDs use was 0.94 (95% CI: 0.92--0.98, *P* = 0.001) (Figure [6](#F6){ref-type="fig"}), increasing per 2 year of duration of non-aspirin NSAIDs use was associated with a 8% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per 2 year of duration of non-aspirin NSAIDs use was 0.92 (95% CI: 0.87--0.97, *P* = 0.001) (Figure [7](#F7){ref-type="fig"}), increasing per 2 year of duration of aspirin use was associated with a 6% decrement of CNS tumors risk, the summary relative risk of CNS tumors risk for an per 2 year of duration of aspirin use was 0.94 (95% CI: 0.88--0.98, *P* = 0.005) (Figure [8](#F8){ref-type="fig"}).

![Dose-response relationship between cumulative daily dose of NSAIDs use in relation to risk of central nervous system tumor](oncotarget-08-102486-g002){#F2}

![Dose-response relationship between number of prescriptions of NSAIDs use in relation to risk of central nervous system tumor](oncotarget-08-102486-g003){#F3}

![Dose-response relationship between number of prescriptions of non-aspirin NSAIDs use in relation to risk of central nervous system tumor](oncotarget-08-102486-g004){#F4}

![Dose-response relationship between number of prescriptions of aspirin use in relation to risk of central nervous system tumor](oncotarget-08-102486-g005){#F5}

![Dose-response relationship between duration of NSAIDs use in relation to risk of central nervous system tumor](oncotarget-08-102486-g006){#F6}

![Dose-response relationship between duration of non-aspirin NSAIDs use in relation to risk of central nervous system tumor](oncotarget-08-102486-g007){#F7}

![Dose-response relationship between duration of aspirin use in relation to risk of central nervous system tumor](oncotarget-08-102486-g008){#F8}

Subgroup analyses {#s2_7}
-----------------

Subgroup analysis was performed to check the stability of the primary outcome. Subgroup meta-analyses in study design, study quality, number of participants and number of cases showed consistent findings (Tables [3](#T3){ref-type="table"}--[5](#T5){ref-type="table"}).

Sensitivity analysis {#s2_8}
--------------------

Sensitivity analysis was conducted to assess the stability of the results. The results show the association between NSAIDs use and CNS tumors risk were stable ([Supplementary Figures 1](#SD1){ref-type="supplementary-material"}--[3](#SD1){ref-type="supplementary-material"}).

Publication bias {#s2_9}
----------------

Publication bias of NSAIDs use was evaluated with both Begg\'s and Egger\'s tests. Results from Egger\'s tests indicated no evidence of publication bias among these studies ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). A funnel plot for publication bias assessment is illustrated in [Supplementary Figures 4](#SD1){ref-type="supplementary-material"}--[6](#SD1){ref-type="supplementary-material"}.

DISCUSSION {#s3}
==========

In the current meta-analysis was based on 12 case-control or cohort study, with 667085 participants with 19394 incident cases. Thus, this meta analysis provides the most up-to-date epidemiological evidence supporting NSAIDs use is helpful for CNS tumors. A dose-response analysis revealed that increasing cumulative 100 defined daily dose of NSAIDs use was associated with a 5% decrement of CNS tumors risk, increasing NSAIDs or non-aspirin NSAIDs or aspirin use (per 3 prescriptions increment) was associated with a 7%, 7%, 10% decrement of CNS tumors risk, increasing per 2 year of duration of NSAIDs or non-aspirin NSAIDs or aspirin use was associated with a 6%, 8%, 6% decrement of CNS tumors risk.

Previous meta-analysis reported the association between NSAIDs use and brain tumour risk, and found NSAIDs use did not appear to be associated with brain tumour risk \[[@R24]\]. Though, the result is quite different with ours, it still exist some problems. On the one hand, previous meta-analysis included just ten reports from ten studies, our meta-analysis included thirty-three independent reports from twelve studies, the quantity of reports involving in their meta-analysis was smaller, which weak the persuasive power of their research, and our results become more convincing. On the other hand, previous meta-analysis did not include all NSAIDs in the study, this may be affect the result and all NSAIDs acted as a independent report in our meta-analysis.

Several plausible pathways may reasonable for the relationship between NSAIDs use and CNS tumors risk. Firstly, NSAIDs have been found to inhibit or kill glioma cells, and the nonsteroidal anti-inflammatory drug can suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway \[[@R25]--[@R27]\]. Secondly, refractoriness of glioblastoma multiforme (GBM) largely depends on its radioresistance, and celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress \[[@R28]--[@R31]\]. Third, NSAIDs use can significantly enhance glioblastoma radiosensitivity, reduced clonogenic survival, and prolonged survival of glioblastoma-implanted mice by inhibition of tumor angiogenesis with extensive tumor necrosis and reduce angiogenesis \[[@R32]--[@R34]\]. Fourth, NSAIDs use is sufficient to render unmodified tumor cells immunogenic in immunotherapy of experimental brain tumors, and stimulate anti-tumour immune reactions *in vitro* and in established animal models \[[@R35]--[@R37]\]. However, the potential mechanisms of NSAIDs use and tumor growth still remain unclear and controversial.

To our knowledge, this is the first comprehensive study to identify and quantify the potential dose-response association between NSAIDs use and CNS tumors risk in both men and women. Although, we performed this meta-analysis very carefully, some limitations must be considered in the current meta-analysis. Firstly, despite we searched all studies describing the association between NSAIDs use and CNS tumors risk, there are only 12 studies about NSAIDs use and CNS tumors risk, the number of eligible studies was still limited. On the other hand, 12 studies from only three countries, different ethnic population are warranted to validate the association between NSAIDs use and CNS tumors risk. Thirdly, we only select literature that written by English, which may have resulted in a language or cultural bias, other languages should be chosen in the further. Fourth, in the subgroup analysis in CNS tumors type, there has no insufficient statistical power to check a dose-response in different CNS tumors type, large data in different CNS tumors type is warranted to validate this association.

In conclusion, our findings underscore the notion that NSAIDs use was significantly associated with CNS tumors risk decrement. In the future, large-scale case-control and population based association studies must be performed in the future to validate the risk identified in the current meta-analysis.

MATERIALS AND METHODS {#s4}
=====================

Our meta-analysis was conducted according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) checklist \[[@R38]\].

Search strategy {#s4_1}
---------------

We included eligible studies investigating the relationship of NSAIDs use and CNS tumors risk. To develop a flexible, non-linear, r meta-regression model, we required that an eligible study should have categorized into 3 or more levels.

Eligible studies were systematically searched of PubMed and Embase update to July 2017 for case control or cohort studies examining the relationship between NSAIDs use and CNS tumors risk, with keywords including "brain cancer" \[MeSH\] OR "glioma"\[MeSH\] OR "glioblastoma" \[MeSH\] OR "meningioma" \[MeSH\] AND "aspirin" \[MeSH\] OR "NSAIDs" \[MeSH\] OR "ibuprofen"\[MeSH\] OR "naproxen" \[MeSH\] OR "indomethacin" \[MeSH\] OR "meloxicam" \[MeSH\] OR "nimesulide" \[MeSH\] OR "celecoxib" \[MeSH\] OR "rofecoxib"\[MeSH\] OR "acetaminophen" \[MeSH\] OR "diclofenac"\[MeSH\]. We refer to the relevant original essays and commentary articles to determine further relevant research.

Study selection {#s4_2}
---------------

Two independent researchers investigate information the correlation between NSAIDs use and CNS tumors risk: outcome was CNS tumors; the relative risks at least three quantitative categories of NSAIDs use and CNS tumors risk. Moreover, we precluded non-human studies, reviews, editorials and published letters.

Data extraction {#s4_3}
---------------

Use standardized data collection tables to extract data. We extracted the following information: first author; publication year; age; country; sex; cases and participants; the categories of NSAIDs use; relative risk(RR) or odds ratio (OR). We collect the risk estimates with multivariable-adjusted. According to the Newcastle-Ottawa scale \[[@R39]\], quality assessment was performed for non-randomized studies.

Statistical analysis {#s4_4}
--------------------

We pooled relative risk estimates to measure the association between NSAIDs use and CNS tumors risk; the hazard ratio were considered equivalent to the relative risk \[[@R40]\]. Results in different subgroups of NSAIDs use and CNS tumors risk were treated as two separate reports.

Due to different definitions cut-off points in the included studies for categories, we performed a relative risk estimates by increasing cumulative 100 defined daily dose of NSAIDs use or per 3 prescriptions of NSAIDs use or per 2 year of duration of NSAIDs use the method recommended by Greenland, Longnecker and Orsini and colleagues \[[@R41]\]. In addition, use restricted cubic splines to evaluate the non-linear association between NSAIDs use and CNS tumors risk, with three knots at the 10th, 50th, and 90th percentiles of the distribution. A flexible meta-regression based on restricted cubic spline (RCS) function was used to fit the potential non-linear trend, and generalized least-square method was used to estimate the parameters. This procedure treats NSAIDs use (continuous data) as an independent variable and logRR of diseases as a dependent variable, with both tails of the curve restricted to linear. A *P* value is calculated for linear or non-linear by testing the null hypothesis that the coefficient of the second spline is equal to zero \[[@R42]\].

We use STATA software 12.0 (STATA Corp, College Station, TX, USA) to evaluate the relationships between NSAIDs use and CNS tumors risk. Heterogeneity among studies used Q test and I^2^ statistic to assess. If *P*~Q~\< 0.10 or I^2^ \> 50%, random-effect model was chosen, otherwise, fixed-effect mode was applied. Begg\'s and Egger\'s tests were to assess the publication bias of each study. *P* \< 0.05 was considered signifcant for all tests.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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